Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal composition for preventing or treating Th1 type immunological disease

A technology for immune diseases and autoimmune diseases, which is applied in the field of pharmaceutical compositions for preventing or treating Th1 type immune diseases, and achieves the effect of small side effects

Inactive Publication Date: 2006-08-09
ASUBIO PHARMA
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are absolutely no reports on the physiological function or pathophysiological significance of substances that act on GC-A derived from human monocytes related to the immune system to promote cGMP production, or immunomodulatory effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for preventing or treating Th1 type immunological disease
  • Medicinal composition for preventing or treating Th1 type immunological disease
  • Medicinal composition for preventing or treating Th1 type immunological disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0083] Example 1 Expression of GC-A gene on immature dendritic cells and activity of promoting cGMP production by ANP

[0084] The inventors of the present invention first studied the expression of three NP receptor genes in dendritic cells and monocytes. RNA was prepared from monocytes and immature dendritic cells obtained from normal human peripheral blood, and the gene expression of NP receptors GC-A, GC-B, and NPR-C was discussed by RT-PCR method. The results are as follows figure 1 shown.

[0085] It was confirmed that all three NP receptor genes were expressed in the placenta-derived RNA used as a positive control. It was clearly confirmed that only the GC-A gene was expressed in immature dendritic cells relative to no expression of any receptor genes in monocytes. Therefore, it was confirmed that the NP receptor gene was not expressed in monocytes, and the GC-A gene was specifically expressed in monocyte-derived dendritic cells.

[0086] Then, in order to elucidate w...

Embodiment 2

[0088] Example 2 Research on the effect of ANP on the expression of cytokines and Th2 tendency of dendritic cells

[0089] From the results of Example 1, it can be known that ANP acts on dendritic cells and can regulate the immune response.

[0090] An important function of dendritic cells is to elicit antigen-specific immune responses from naive T cells. Therefore, first, the effect of adding ANP to dendritic cells in the presence and absence of LPS, which is known to mature and activate dendritic cells, is involved in the activation, proliferation response against naive T cells research. The result is as image 3 shown.

[0091] ANP alone did not affect the proliferative response of naïve T cells, but once LPS was added to dendritic cells, it elicited a significant T cell proliferative response.

[0092] On the other hand, it is known that T cell proliferation induced by LPS-treated dendritic cells can be almost completely suppressed when both ANP and LPS are added.

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

To provide a medicinal composition for preventing or treating a Th1 type immunological disease. A medicinal composition to be used in preventing or treating a Th1 type immunological disease containing as the active ingredient a substance capable of differentiating T cells into Th2 type cells by acting on GC-A, which is an NP receptor expressed in dendritic cells, to thereby promote cGMP production and control the cytokine production in the dendritic cells is obtained.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for the prevention or treatment of Th1 type immune diseases containing, as an active ingredient, a substance capable of acting on receptors of natriuretic peptide (NP) expressed in dendritic cells Glycylate cyclase A (GC-A), which promotes the production of cyclic guanosine monophosphate (cGMP). Background technique [0002] The immune system originally evolved as a defense mechanism to recognize and eliminate foreign substances (microorganisms, etc.). Therefore, the body can distinguish its own cells or tissues from foreign foreign bodies (non-self), and does not respond to itself, or even if it responds, it continues to maintain a state of inability to function (immune tolerance), so that it can be quickly and effectively eliminated. Non-self acquired immunity is maturing day by day. Playing a central role in acquired immunity are T cells. Undifferentiated peripheral primitive T cells (...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K38/22A61P37/00A61P1/02A61P1/04A61P3/10A61P7/06A61P9/00A61P17/00A61P17/06A61P19/02A61P21/00A61P21/04A61P25/00A61P29/00A61P43/00C12N5/07
CPCA61K38/2242A61P1/00A61P1/02A61P1/04A61P1/16A61P17/00A61P17/06A61P19/02A61P21/00A61P21/04A61P25/00A61P29/00A61P3/10A61P37/00A61P37/02A61P43/00A61P5/14A61P7/00A61P7/06A61P9/00A61K45/00A61K38/22
Inventor 堀利行
Owner ASUBIO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com